Point72 DIFC Ltd Sells 3,955 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

Point72 DIFC Ltd reduced its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) by 17.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,987 shares of the medical instruments supplier’s stock after selling 3,955 shares during the period. Point72 DIFC Ltd’s holdings in OraSure Technologies were worth $81,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Marshall Wace LLP purchased a new position in OraSure Technologies during the second quarter valued at approximately $203,000. Sei Investments Co. lifted its stake in OraSure Technologies by 76.9% in the 2nd quarter. Sei Investments Co. now owns 302,043 shares of the medical instruments supplier’s stock worth $1,287,000 after purchasing an additional 131,295 shares in the last quarter. Inspire Investing LLC bought a new position in OraSure Technologies in the 2nd quarter valued at $734,000. Hsbc Holdings PLC grew its position in shares of OraSure Technologies by 470.6% during the 2nd quarter. Hsbc Holdings PLC now owns 200,779 shares of the medical instruments supplier’s stock valued at $850,000 after purchasing an additional 165,590 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of OraSure Technologies by 20.6% in the second quarter. Renaissance Technologies LLC now owns 2,288,443 shares of the medical instruments supplier’s stock worth $9,749,000 after purchasing an additional 391,100 shares during the period. 93.50% of the stock is currently owned by hedge funds and other institutional investors.

OraSure Technologies Price Performance

OSUR opened at $4.29 on Friday. OraSure Technologies, Inc. has a 1 year low of $3.91 and a 1 year high of $8.45. The stock’s 50 day simple moving average is $4.32 and its 200 day simple moving average is $4.86. The firm has a market cap of $317.28 million, a price-to-earnings ratio of 14.30 and a beta of 0.05.

OraSure Technologies (NASDAQ:OSUR) last issued its earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.03 EPS for the quarter. The company had revenue of $54.34 million for the quarter, compared to the consensus estimate of $53.35 million. OraSure Technologies had a net margin of 9.88% and a return on equity of 9.15%. As a group, sell-side analysts anticipate that OraSure Technologies, Inc. will post -0.11 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Evercore ISI lifted their price objective on OraSure Technologies from $4.50 to $5.00 and gave the company an “in-line” rating in a research note on Wednesday, August 7th. StockNews.com cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Saturday, August 17th. Three equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $6.67.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.